Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04141995 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04141995: Clinical Trial Phase 2 study, sponsored by University of Nebraska.
NCT04141995 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04141995, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in participants with resectable pancreatic cancer.
Primary Outcome
Regimen will be considered for further investigation if 14 of the 20 patients are able to undergo resection
Interventions
- DRUG Oxaliplatin
- DRUG Irinotecan
- DRUG 5Fluorouracil
- DRUG Digoxin
- DRUG Calcium Leucovorin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2025-05-13 |
| Phase | Phase 2 |
Why NCT04141995 stopped before completion
NCT04141995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT04141995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04141995 about?
NCT04141995 is a clinical study titled "FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer". The purpose of this study is to determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in participants with resectable pancreatic cancer.
What is the current status of trial NCT04141995?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2021-02-12. Estimated completion is 2025-05-13.
What interventions are being tested in trial NCT04141995?
The interventions under investigation include: Oxaliplatin (DRUG), Irinotecan (DRUG), 5Fluorouracil (DRUG), Digoxin (DRUG), Calcium Leucovorin (DRUG).
Who is sponsoring clinical trial NCT04141995?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04141995's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI